Effects  ||| S:0 E:8 ||| NNS
of  ||| S:8 E:11 ||| IN
prior  ||| S:11 E:17 ||| JJ
exercise  ||| S:17 E:26 ||| NN
on  ||| S:26 E:29 ||| IN
insulin-mediated  ||| S:29 E:46 ||| JJ
and  ||| S:46 E:50 ||| CC
noninsulin-mediated  ||| S:50 E:70 ||| JJ
glucose  ||| S:70 E:78 ||| JJ
uptake  ||| S:78 E:85 ||| NN
in  ||| S:85 E:88 ||| IN
horses  ||| S:88 E:95 ||| NNS
during  ||| S:95 E:102 ||| IN
a  ||| S:102 E:104 ||| DT
hyperglycaemic  ||| S:104 E:119 ||| JJ
clamp  ||| S:119 E:125 ||| NN
There  ||| S:125 E:131 ||| EX
is  ||| S:131 E:134 ||| VBZ
limited  ||| S:134 E:142 ||| JJ
information  ||| S:142 E:154 ||| NN
about  ||| S:154 E:160 ||| IN
factors  ||| S:160 E:168 ||| NNS
regulating  ||| S:168 E:179 ||| VBG
glucose  ||| S:179 E:187 ||| JJ
utilisation  ||| S:187 E:199 ||| JJ
post  ||| S:199 E:204 ||| NN
exercise  ||| S:204 E:213 ||| NN
in  ||| S:213 E:216 ||| IN
horses ||| S:216 E:222 ||| NNS
.  ||| S:222 E:224 ||| .
To  ||| S:224 E:227 ||| TO
determine  ||| S:227 E:237 ||| VB
the  ||| S:237 E:241 ||| DT
effects  ||| S:241 E:249 ||| NNS
of  ||| S:249 E:252 ||| IN
a  ||| S:252 E:254 ||| DT
single  ||| S:254 E:261 ||| JJ
bout  ||| S:261 E:266 ||| NN
of  ||| S:266 E:269 ||| IN
moderate  ||| S:269 E:278 ||| JJ
intensity  ||| S:278 E:288 ||| NN
exercise  ||| S:288 E:297 ||| NN
on  ||| S:297 E:300 ||| IN
measures  ||| S:300 E:309 ||| NNS
of  ||| S:309 E:312 ||| IN
insulin-mediated  ||| S:312 E:329 ||| NNP
( ||| S:329 E:330 ||| -LRB-
IMGU ||| S:330 E:334 ||| NNP
)  ||| S:334 E:336 ||| -RRB-
and  ||| S:336 E:340 ||| CC
noninsulin-mediated  ||| S:340 E:360 ||| NNP
( ||| S:360 E:361 ||| -LRB-
NIMGU ||| S:361 E:366 ||| NNP
)  ||| S:366 E:368 ||| -RRB-
glucose  ||| S:368 E:376 ||| JJ
uptake  ||| S:376 E:383 ||| NN
during  ||| S:383 E:390 ||| IN
a  ||| S:390 E:392 ||| DT
hyperglycaemic  ||| S:392 E:407 ||| JJ
clamp  ||| S:407 E:413 ||| NNS
( ||| S:413 E:414 ||| -LRB-
HC ||| S:414 E:416 ||| NNP
) ||| S:416 E:417 ||| -RRB-
.  ||| S:417 E:419 ||| .
Hyperglycaemic  ||| S:419 E:434 ||| JJ
clamps  ||| S:434 E:441 ||| NN
were  ||| S:441 E:446 ||| VBD
administered  ||| S:446 E:459 ||| VBN
in  ||| S:459 E:462 ||| IN
random  ||| S:462 E:469 ||| JJ
order  ||| S:469 E:475 ||| NN
to  ||| S:475 E:478 ||| TO
8  ||| S:478 E:480 ||| CD
Standardbreds  ||| S:480 E:494 ||| NNS
under  ||| S:494 E:500 ||| IN
4  ||| S:500 E:502 ||| CD
conditions ||| S:502 E:512 ||| NNS
:  ||| S:512 E:514 ||| :
1 ||| S:514 E:515 ||| LS
)  ||| S:515 E:517 ||| -RRB-
rest ||| S:517 E:521 ||| NN
,  ||| S:521 E:523 ||| ,
insulinopenia  ||| S:523 E:537 ||| NNS
( ||| S:537 E:538 ||| -LRB-
R-L ||| S:538 E:541 ||| NNP
) ||| S:541 E:542 ||| -RRB-
;  ||| S:542 E:544 ||| :
2 ||| S:544 E:545 ||| LS
)  ||| S:545 E:547 ||| -RRB-
rest ||| S:547 E:551 ||| NN
,  ||| S:551 E:553 ||| ,
hyperinsulinaemia  ||| S:553 E:571 ||| NNS
( ||| S:571 E:572 ||| -LRB-
R-H ||| S:572 E:575 ||| NNP
) ||| S:575 E:576 ||| -RRB-
;  ||| S:576 E:578 ||| :
3 ||| S:578 E:579 ||| LS
)  ||| S:579 E:581 ||| -RRB-
post  ||| S:581 E:586 ||| NN
exercise  ||| S:586 E:595 ||| NN
( ||| S:595 E:596 ||| -LRB-
45  ||| S:596 E:599 ||| CD
min  ||| S:599 E:603 ||| NN
at  ||| S:603 E:606 ||| IN
∼  ||| S:606 E:608 ||| CD
50 ||| S:608 E:610 ||| CD
%  ||| S:610 E:612 ||| NN
VO2peak ||| S:612 E:619 ||| CD
) ||| S:619 E:620 ||| -RRB-
,  ||| S:620 E:622 ||| ,
insulinopenia  ||| S:622 E:636 ||| NNS
( ||| S:636 E:637 ||| -LRB-
Ex-L ||| S:637 E:641 ||| NNP
)  ||| S:641 E:643 ||| -RRB-
and  ||| S:643 E:647 ||| CC
4 ||| S:647 E:648 ||| LS
)  ||| S:648 E:650 ||| -RRB-
post  ||| S:650 E:655 ||| NN
exercise ||| S:655 E:663 ||| NN
,  ||| S:663 E:665 ||| ,
hyperinsulinaemia  ||| S:665 E:683 ||| NNS
( ||| S:683 E:684 ||| -LRB-
Ex-H ||| S:684 E:688 ||| NNP
) ||| S:688 E:689 ||| -RRB-
.  ||| S:689 E:691 ||| .
In  ||| S:691 E:694 ||| IN
the  ||| S:694 E:698 ||| DT
R-L  ||| S:698 E:702 ||| JJ
and  ||| S:702 E:706 ||| CC
Ex-L  ||| S:706 E:711 ||| JJ
trials ||| S:711 E:717 ||| NNS
,  ||| S:717 E:719 ||| ,
somatostatin  ||| S:719 E:732 ||| NN
was  ||| S:732 E:736 ||| VBD
infused  ||| S:736 E:744 ||| VBN
to  ||| S:744 E:747 ||| TO
suppress  ||| S:747 E:756 ||| VB
insulin  ||| S:756 E:764 ||| NN
secretion  ||| S:764 E:774 ||| NNS
and  ||| S:774 E:778 ||| CC
induce  ||| S:778 E:785 ||| VB
insulinopenia ||| S:785 E:798 ||| NNS
.  ||| S:798 E:800 ||| .
After  ||| S:800 E:806 ||| IN
30  ||| S:806 E:809 ||| CD
min ||| S:809 E:812 ||| NN
,  ||| S:812 E:814 ||| ,
a  ||| S:814 E:816 ||| DT
2  ||| S:816 E:818 ||| CD
h  ||| S:818 E:820 ||| JJ
HC  ||| S:820 E:823 ||| NNP
was  ||| S:823 E:827 ||| VBD
initiated  ||| S:827 E:837 ||| VBN
with  ||| S:837 E:842 ||| IN
plasma  ||| S:842 E:849 ||| JJ
glucose  ||| S:849 E:857 ||| NN
concentrations  ||| S:857 E:872 ||| NNS
maintained  ||| S:872 E:883 ||| VBN
at  ||| S:883 E:886 ||| IN
∼  ||| S:886 E:888 ||| CD
10  ||| S:888 E:891 ||| CD
mmol ||| S:891 E:895 ||| CD
/ ||| S:895 E:896 ||| CD
l  ||| S:896 E:898 ||| NN
by  ||| S:898 E:901 ||| IN
variable  ||| S:901 E:910 ||| JJ
glucose  ||| S:910 E:918 ||| JJ
infusion ||| S:918 E:926 ||| NN
.  ||| S:926 E:928 ||| .
In  ||| S:928 E:931 ||| IN
R-H  ||| S:931 E:935 ||| JJ
and  ||| S:935 E:939 ||| CC
Ex-H ||| S:939 E:943 ||| JJ
,  ||| S:943 E:945 ||| ,
regular  ||| S:945 E:953 ||| JJ
insulin  ||| S:953 E:961 ||| NN
( ||| S:961 E:962 ||| -LRB-
1.0  ||| S:962 E:966 ||| FW
mu ||| S:966 E:968 ||| FW
/ ||| S:968 E:969 ||| FW
kg  ||| S:969 E:972 ||| FW
bwt ||| S:972 E:975 ||| FW
/ ||| S:975 E:976 ||| FW
min ||| S:976 E:979 ||| FW
)  ||| S:979 E:981 ||| -RRB-
was  ||| S:981 E:985 ||| VBD
also  ||| S:985 E:990 ||| RB
administered  ||| S:990 E:1003 ||| VBN
to  ||| S:1003 E:1006 ||| TO
induce  ||| S:1006 E:1013 ||| VB
physiological  ||| S:1013 E:1027 ||| JJ
hyperinsulinaemia ||| S:1027 E:1044 ||| NN
.  ||| S:1044 E:1046 ||| .
Serum  ||| S:1046 E:1052 ||| JJ
insulin  ||| S:1052 E:1060 ||| NN
and  ||| S:1060 E:1064 ||| CC
C-peptide  ||| S:1064 E:1074 ||| JJ
concentrations  ||| S:1074 E:1089 ||| NNS
were  ||| S:1089 E:1094 ||| VBD
measured  ||| S:1094 E:1103 ||| VBN
in  ||| S:1103 E:1106 ||| IN
samples  ||| S:1106 E:1114 ||| NNS
obtained  ||| S:1114 E:1123 ||| VBN
at  ||| S:1123 E:1126 ||| IN
10  ||| S:1126 E:1129 ||| CD
min  ||| S:1129 E:1133 ||| CD
intervals ||| S:1133 E:1142 ||| NNS
.  ||| S:1142 E:1144 ||| .
Glucose  ||| S:1144 E:1152 ||| JJ
uptake  ||| S:1152 E:1159 ||| NN
was  ||| S:1159 E:1163 ||| VBD
calculated  ||| S:1163 E:1174 ||| VBN
from  ||| S:1174 E:1179 ||| IN
mean  ||| S:1179 E:1184 ||| JJ
glucose  ||| S:1184 E:1192 ||| JJ
infusion  ||| S:1192 E:1201 ||| NN
rate  ||| S:1201 E:1206 ||| NN
( ||| S:1206 E:1207 ||| -LRB-
GIR ||| S:1207 E:1210 ||| NNP
)  ||| S:1210 E:1212 ||| -RRB-
during  ||| S:1212 E:1219 ||| IN
the  ||| S:1219 E:1223 ||| DT
last  ||| S:1223 E:1228 ||| JJ
60  ||| S:1228 E:1231 ||| CD
min  ||| S:1231 E:1235 ||| NN
of  ||| S:1235 E:1238 ||| IN
the  ||| S:1238 E:1242 ||| DT
HC ||| S:1242 E:1244 ||| NNP
.  ||| S:1244 E:1246 ||| .
In  ||| S:1246 E:1249 ||| IN
all  ||| S:1249 E:1253 ||| DT
HCs  ||| S:1253 E:1257 ||| JJ
C-peptide  ||| S:1257 E:1267 ||| NN
remained  ||| S:1267 E:1276 ||| VBD
below  ||| S:1276 E:1282 ||| IN
baseline  ||| S:1282 E:1291 ||| NN
concentrations ||| S:1291 E:1305 ||| NNS
,  ||| S:1305 E:1307 ||| ,
evidence  ||| S:1307 E:1316 ||| NN
of  ||| S:1316 E:1319 ||| IN
suppression  ||| S:1319 E:1331 ||| NN
of  ||| S:1331 E:1334 ||| IN
insulin  ||| S:1334 E:1342 ||| NN
secretion  ||| S:1342 E:1352 ||| NN
by  ||| S:1352 E:1355 ||| IN
somatostatin ||| S:1355 E:1367 ||| NN
.  ||| S:1367 E:1369 ||| .
Overall ||| S:1369 E:1376 ||| RB
,  ||| S:1376 E:1378 ||| ,
mean  ||| S:1378 E:1383 ||| VB
±  ||| S:1383 E:1385 ||| CD
s.e.  ||| S:1385 E:1390 ||| CD
insulin  ||| S:1390 E:1398 ||| NN
concentrations  ||| S:1398 E:1413 ||| NNS
during  ||| S:1413 E:1420 ||| IN
the  ||| S:1420 E:1424 ||| DT
final  ||| S:1424 E:1430 ||| JJ
60  ||| S:1430 E:1433 ||| CD
min  ||| S:1433 E:1437 ||| NN
of  ||| S:1437 E:1440 ||| IN
the  ||| S:1440 E:1444 ||| DT
HC  ||| S:1444 E:1447 ||| NNP
in  ||| S:1447 E:1450 ||| IN
R-L  ||| S:1450 E:1454 ||| JJ
and  ||| S:1454 E:1458 ||| CC
Ex-L  ||| S:1458 E:1463 ||| NNP
were  ||| S:1463 E:1468 ||| VBD
5.7  ||| S:1468 E:1472 ||| CD
±  ||| S:1472 E:1474 ||| CD
1.1  ||| S:1474 E:1478 ||| CD
and  ||| S:1478 E:1482 ||| CC
6.9  ||| S:1482 E:1486 ||| CD
±  ||| S:1486 E:1488 ||| CD
1.9  ||| S:1488 E:1492 ||| CD
mu ||| S:1492 E:1494 ||| CD
/ ||| S:1494 E:1495 ||| CD
l  ||| S:1495 E:1497 ||| NNS
respectively ||| S:1497 E:1509 ||| RB
,  ||| S:1509 E:1511 ||| ,
and  ||| S:1511 E:1515 ||| CC
corresponding  ||| S:1515 E:1529 ||| JJ
values  ||| S:1529 E:1536 ||| NNS
in  ||| S:1536 E:1539 ||| IN
R-H  ||| S:1539 E:1543 ||| JJ
and  ||| S:1543 E:1547 ||| CC
Ex-H  ||| S:1547 E:1552 ||| NNP
were  ||| S:1552 E:1557 ||| VBD
64.1  ||| S:1557 E:1562 ||| CD
±  ||| S:1562 E:1564 ||| CD
11.1  ||| S:1564 E:1569 ||| CD
and  ||| S:1569 E:1573 ||| CC
61.2  ||| S:1573 E:1578 ||| CD
±  ||| S:1578 E:1580 ||| CD
10.9  ||| S:1580 E:1585 ||| CD
mu ||| S:1585 E:1587 ||| CD
/ ||| S:1587 E:1588 ||| CD
l ||| S:1588 E:1589 ||| NN
.  ||| S:1589 E:1591 ||| .
Prior  ||| S:1591 E:1597 ||| RB
exercise  ||| S:1597 E:1606 ||| VB
affected  ||| S:1606 E:1615 ||| VBN
IMGU  ||| S:1615 E:1620 ||| NNP
but  ||| S:1620 E:1624 ||| CC
not  ||| S:1624 E:1628 ||| RB
NIMGU ||| S:1628 E:1633 ||| NNP
.  ||| S:1633 E:1635 ||| .
Over  ||| S:1635 E:1640 ||| IN
the  ||| S:1640 E:1644 ||| DT
final  ||| S:1644 E:1650 ||| JJ
60  ||| S:1650 E:1653 ||| CD
min  ||| S:1653 E:1657 ||| NN
of  ||| S:1657 E:1660 ||| IN
the  ||| S:1660 E:1664 ||| DT
HC ||| S:1664 E:1666 ||| NNP
,  ||| S:1666 E:1668 ||| ,
mean  ||| S:1668 E:1673 ||| VB
GIR  ||| S:1673 E:1677 ||| NNP
was  ||| S:1677 E:1681 ||| VBD
higher  ||| S:1681 E:1688 ||| JJR
( ||| S:1688 E:1689 ||| -LRB-
P  ||| S:1689 E:1691 ||| NNP
< ||| S:1691 E:1693 ||| SYM
0.001 ||| S:1693 E:1698 ||| NNP
)  ||| S:1698 E:1700 ||| -RRB-
in  ||| S:1700 E:1703 ||| IN
Ex-H  ||| S:1703 E:1708 ||| NNP
( ||| S:1708 E:1709 ||| -LRB-
5.6  ||| S:1709 E:1713 ||| CD
±  ||| S:1713 E:1715 ||| CD
1.1  ||| S:1715 E:1719 ||| CD
mg ||| S:1719 E:1721 ||| FW
/ ||| S:1721 E:1722 ||| FW
kg  ||| S:1722 E:1725 ||| FW
bwt ||| S:1725 E:1728 ||| FW
/ ||| S:1728 E:1729 ||| FW
min ||| S:1729 E:1732 ||| FW
)  ||| S:1732 E:1734 ||| -RRB-
than  ||| S:1734 E:1739 ||| IN
in  ||| S:1739 E:1742 ||| IN
R-H  ||| S:1742 E:1746 ||| NNP
( ||| S:1746 E:1747 ||| -LRB-
3.3  ||| S:1747 E:1751 ||| CD
±  ||| S:1751 E:1753 ||| CD
0.9  ||| S:1753 E:1757 ||| CD
mg ||| S:1757 E:1759 ||| FW
/ ||| S:1759 E:1760 ||| FW
kg  ||| S:1760 E:1763 ||| FW
bwt ||| S:1763 E:1766 ||| FW
/ ||| S:1766 E:1767 ||| FW
min ||| S:1767 E:1770 ||| FW
) ||| S:1770 E:1771 ||| -RRB-
,  ||| S:1771 E:1773 ||| ,
whereas  ||| S:1773 E:1781 ||| RB
mean  ||| S:1781 E:1786 ||| VB
GIR  ||| S:1786 E:1790 ||| NNP
did  ||| S:1790 E:1794 ||| VBD
not  ||| S:1794 E:1798 ||| RB
differ  ||| S:1798 E:1805 ||| VB
( ||| S:1805 E:1806 ||| -LRB-
P  ||| S:1806 E:1808 ||| NN
=  ||| S:1808 E:1810 ||| SYM
0.26 ||| S:1810 E:1814 ||| CD
)  ||| S:1814 E:1816 ||| -RRB-
between  ||| S:1816 E:1824 ||| IN
R-L  ||| S:1824 E:1828 ||| NNP
( ||| S:1828 E:1829 ||| -LRB-
1.2  ||| S:1829 E:1833 ||| CD
±  ||| S:1833 E:1835 ||| CD
0.3  ||| S:1835 E:1839 ||| CD
mg ||| S:1839 E:1841 ||| FW
/ ||| S:1841 E:1842 ||| FW
kg  ||| S:1842 E:1845 ||| FW
bwt ||| S:1845 E:1848 ||| FW
/ ||| S:1848 E:1849 ||| FW
min ||| S:1849 E:1852 ||| FW
)  ||| S:1852 E:1854 ||| -RRB-
and  ||| S:1854 E:1858 ||| CC
Ex-L  ||| S:1858 E:1863 ||| NNP
( ||| S:1863 E:1864 ||| -LRB-
1.8  ||| S:1864 E:1868 ||| CD
±  ||| S:1868 E:1870 ||| CD
0.5  ||| S:1870 E:1874 ||| CD
mg ||| S:1874 E:1876 ||| FW
/ ||| S:1876 E:1877 ||| FW
kg  ||| S:1877 E:1880 ||| FW
bwt ||| S:1880 E:1883 ||| FW
/ ||| S:1883 E:1884 ||| FW
min ||| S:1884 E:1887 ||| FW
) ||| S:1887 E:1888 ||| -RRB-
.  ||| S:1888 E:1890 ||| .
A  ||| S:1890 E:1892 ||| DT
single  ||| S:1892 E:1899 ||| JJ
bout  ||| S:1899 E:1904 ||| NN
of  ||| S:1904 E:1907 ||| IN
moderate  ||| S:1907 E:1916 ||| JJ
intensity  ||| S:1916 E:1926 ||| NN
exercise  ||| S:1926 E:1935 ||| NN
increased  ||| S:1935 E:1945 ||| VBD
glucose  ||| S:1945 E:1953 ||| JJ
uptake  ||| S:1953 E:1960 ||| NN
during  ||| S:1960 E:1967 ||| IN
a  ||| S:1967 E:1969 ||| DT
hyperglycaemic  ||| S:1969 E:1984 ||| JJ
clamp  ||| S:1984 E:1990 ||| NN
under  ||| S:1990 E:1996 ||| IN
hyperinsulinaemic  ||| S:1996 E:2014 ||| JJ
conditions  ||| S:2014 E:2025 ||| NNS
but  ||| S:2025 E:2029 ||| CC
not  ||| S:2029 E:2033 ||| RB
under  ||| S:2033 E:2039 ||| IN
somatostatin-induced  ||| S:2039 E:2060 ||| JJ
insulinopenia ||| S:2060 E:2073 ||| NN
.  ||| S:2073 E:2075 ||| .
